| Q48225902 | (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression. |
| Q39732144 | A Drosophila model of Huntington disease-like 2 exhibits nuclear toxicity and distinct pathogenic mechanisms from Huntington disease |
| Q50103452 | A Novel Substrate Radiotracer for Molecular Imaging of SIRT2 Expression and Activity with Positron Emission Tomography. |
| Q49590902 | Aberrant DNA methylation associated with Alzheimer's disease in the superior temporal gyrus |
| Q40135749 | Association of Parkinson's Disease GWAS-Linked Loci with Alzheimer's Disease in Han Chinese |
| Q38232821 | Axonal transport defects in Alzheimer's disease |
| Q38224066 | Causes and Consequences of MicroRNA Dysregulation in Neurodegenerative Diseases |
| Q38778638 | Defeating Alzheimer's disease and other dementias: a priority for European science and society |
| Q93108587 | Dysregulation of Epigenetic Mechanisms of Gene Expression in the Pathologies of Hyperhomocysteinemia |
| Q38682574 | Environmental toxicants, incidence of degenerative diseases, and therapies from the epigenetic point of view |
| Q47288935 | Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome |
| Q64060653 | Epigenetic Modulation on Tau Phosphorylation in Alzheimer's Disease |
| Q38225708 | Epigenetic drug discovery for Alzheimer's disease |
| Q38379396 | Epigenetic mechanisms in neurological and neurodegenerative diseases |
| Q37714817 | Epigenetic modifications of chronic hypoxia-mediated neurodegeneration in Alzheimer's disease |
| Q39090345 | Epigenetics in Alzheimer's Disease: Perspective of DNA Methylation |
| Q26772028 | Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response |
| Q85263415 | Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics |
| Q60935279 | Genomics: New Light on Alzheimer's Disease Research |
| Q60368940 | HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease |
| Q26750099 | Hypoxia-Inducible Histone Lysine Demethylases: Impact on the Aging Process and Age-Related Diseases |
| Q35848289 | In situ detection of histone variants and modifications in mouse brain using imaging mass spectrometry |
| Q35903773 | MALDI imaging mass spectrometry as a novel tool for detecting histone modifications in clinical tissue samples |
| Q99347436 | Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective |
| Q58555658 | Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer's and Parkinson's Diseases |
| Q38820807 | Recent Findings in Alzheimer Disease and Nutrition Focusing on Epigenetics |
| Q38121524 | Targeting the mTOR signaling network for Alzheimer's disease therapy |
| Q34426210 | The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity? |
| Q38527233 | The epigenetics of aging and neurodegeneration. |
| Q38237430 | The role of epigenetics in cognitive ageing |
| Q38317697 | The role of microRNAs in toxicology |
| Q53091166 | The synergistic risk effect of apolipoprotein ε4 and DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B) haplotype for Alzheimer's disease. |